EUCTR2012-002526-67-DK进行中（未招募）不适用
Treatment with Liraglutide in type 1 diabetic patients. Effects on glycemic control and counterregulation and cognitive performance during hypoglycaemia.
Sten Madsbad0 个研究点开始时间: 2012年7月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age: 18-70 years
- •BMI: 18-28
- •HbA1c > 8 %
- •Patients without residual ß-cell function, assessed by a glucagon test with stimulated plasma c-peptide < 60 pM.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •Overt diabetes complications; creatinin > 130 µM, proliferativ retinopathy, makroalbinuri, significant heart disease requiring treatment.
- •Autonomic nerve dysfunction
- •Anemia, Hb concentration; female <7.0 mmol/l, male<8.0 mmol/l
- •Pregnancy or lactation (pregnancy test will be done at screening)
- •Previously apopleksia cerebri or any kind of brain pathology.
- •Alcohol or drug abuse
研究者
相似试验
已完成
不适用
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT01299012University at Buffalo30
进行中（未招募）
1 期
iraglutide in type 1 diabetes. A randomised, double-blind, placebo controlled study of the effect of liraglutide as an additional treatment to insulin on HbA1c, body weight and hypoglycaemia in poorly regulated type 1 diabetes patients.Primary objective:To investigate the effect of liraglutide 1.8 mg once daily compared to placebo for 24 weeks on change in HbA1c in patients with type 1 diabetes as an add-on therapy to insulin.Secondary objectives:To investigate the effect of liraglutide as an add-on therapy to insulin compared to placebo on change in:Weight, insulin dose,hypoglycaemic events, CGM, BMI, body composition, quality of life, treatment satisfaction,food preferences, meal test, CIMT, PWV and 24 hour blood pressure.MedDRA version: 14.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-001150-26-DKSteno Diabetes Center
进行中（未招募）
1 期
iraglutide in type 1 diabetes - A randomised, double-blind, placebo-controlled, parallel group, multi-centre trial of 242 liraglutide treatment in subjects with newly-diagnosed type 1 diabetes (The NewLira Study)The effect of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.Also to investigate the effect on postprandial glucagon levels following sustacal meal test, HbA1c, insulin dose, self-monitored blood glucose profile,frequency of hypoglycaemic events, fasting and postprandial cholesterol profile, weight, waist circumference and quality of life. .MedDRA version: 16.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-005317-39-DKDepartment of Endocrinology, Hvidovre Hospital80
已完成
3 期
Liraglutide in Type 1 DiabetesType 1 DiabetesNCT01722240University at Buffalo69
已完成
4 期
Liraglutide in Type 1 DiabetesOverweightDiabetes Mellitus, Type 1NCT01612468Steno Diabetes Center Copenhagen100